Overexpression of URG11 can inhibit the proliferation and motility of breast cancer cells

Breast cancer (BC) is the most common type of cancer among women worldwide, and identifying the key molecules that regulate cell metastasis is essential to improve the patients’ prognosis and developing potential therapeutic strategies. Upregulator gene 11 (URG11) plays a significant role in cancer cell motility. Despite its relevance, its role and underlying mechanism in BC remains underexplored. This study aimed to investigate the significance and mechanism of action of URG11 in BC. The results indicated a low expression of URG11 in BC and revealed that its overexpression could suppress BC cell growth and motility. Through mechanistic studies, we discovered that URG11 overexpression inhibited the Wnt/β-Catenin pathway in BC cells. In summary, URG11 overexpression could inhibit the growth and motility of BC cells by suppressing the Wnt/β-Catenin pathway, suggesting URG11 as a potential target for BC management.

Breast cancer (BC); Upregulator gene 11 (URG11); Invasion; Migration; Wnt/β-catenin

[1] Yang Z, Zhang C, Liu X, Che N, Feng Y, Xuan Y. SETD5 regulates glycolysis in breast cancer stem-like cells and fuels tumor growth. The American Journal of Pathology. 2022; 192: 712–721.

[2] Haffez H, Osman S, Ebrahim HY, Hassan ZA. Growth inhibition and apoptotic effect of pine extract and abietic acid on MCF-7 breast cancer cells via alteration of multiple gene expressions using in vitro approach. Molecules. 2022; 27: 293.

[3] Yang Q, Yan D, Zou C, Xue Q, Lin S, Huang Q, et al. The deubiquitinating enzyme STAMBP is a newly discovered driver of triple-negative breast cancer progression that maintains RAI14 protein stability. Experimental & Molecular Medicine. 2022; 54: 2047–2059.

[4] Wang O, Yang F, Liu Y, Lv L, Ma R, Chen C, et al. C-MYC-induced upregulation of lncRNA SNHG12 regulates cell proliferation, apoptosis and migration in triple-negative breast cancer. American Journal of Translational Research. 2017; 9: 533–545.

[5] Li Y, Jin K, van Pelt GW, van Dam H, Yu X, Mesker WE, et al. c-Myb enhances breast cancer invasion and metastasis through the Wnt/β-catenin/Axin2 pathway. Cancer Research. 2016; 76: 3364–3375.

[6] Thomas-Moore BA, Dedola S, Russell DA, Field RA, Marín MJ. Targeted photodynamic therapy for breast cancer: the potential of glyconanoparticles. Nanoscale Advances. 2023; 5: 6501–6513.

[7] Mahmoudi G, Ehteshaminia Y, Kokhaei P, Jalali SF, Jadidi-Niaragh F, Pagheh AS, et al. Enhancement of targeted therapy in combination with metformin on human breast cancer cell lines. Cell Communication and Signaling. 2024; 22: 10.

[8] Pourjamal N, Yazdi N, Halme A, Joncour VL, Laakkonen P, Saharinen P, et al. Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model. Clinical & Experimental Metastasis. 2024; 41: 91–102.

[9] Pan B, Ye Y, Liu H, Zhen J, Zhou H, Li Y, et al. URG11 regulates prostate cancer cell proliferation, migration, and invasion. BioMed Research International. 2018; 2018: 4060728.

[10] Sun C, Zhang G, Cheng S, Qian H, Li D, Liu M. URG11 promotes proliferation and induced apoptosis of LNCaP cells. International Journal of Molecular Medicine. 2019; 43: 2075–2085.

[11] Zhang G, Zhu F, Han G, Li Z, Yu Q, Li Z, et al. Silencing of URG11 expression inhibits the proliferation and epithelial‑mesenchymal transition in benign prostatic hyperplasia cells via the RhoA/ROCK1 pathway. Molecular Medicine Reports. 2018; 18: 391–398.

[12] Du R, Xia L, Sun S, Lian Z, Zou X, Gao J, et al. URG11 promotes gastric cancer growth and invasion by activation of β-catenin signalling pathway. Journal of Cellular and Molecular Medicine. 2010; 14: 621–635.

[13] Du R, Huang C, Bi Q, Zhai Y, Xia L, Liu J, et al. URG11 mediates hypoxia-induced epithelial-to-mesenchymal transition by modulation of E-cadherin and β-catenin. Biochemical and Biophysical Research Communications. 2010; 391: 135–141.

[14] Wang M, Wu Y, Li X, Dai M, Li S. IGJ suppresses breast cancer growth and metastasis by inhibiting EMT via the NF-kB signaling pathway. International Journal of Oncology. 2023; 63: 105.

[15] Lucarelli AP, Martins MM, Guedes JM. Correlation between the body mass index of patients with breast cancer before and after chemotherapy. European Journal of Gynaecological Oncology. 2017; 38: 187–190.

[16] Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019; 35: 428–440.e5.

[17] Liu ZL, Wu J, Wang LX, Yang JF, Xiao GM, Sun HP, et al. Knockdown of upregulated gene 11 (URG11) inhibits proliferation, invasion, and b-catenin expression in non-small cell lung cancer cells. Oncology Research. 2016; 24: 197–204.

[18] Fan R, Li X, Du W, Zou X, Du R, Zhao L, et al. Adenoviral‐mediated RNA interference targeting URG11 inhibits growth of human hepatocellular carcinoma. International Journal of Cancer. 2011; 128: 2980–2993.

[19] Xie H, Liu J. Increased expression URG11 in hepatocellular carcinoma tissues promotes the growth of hepatocellular carcinoma cells. Chinese Journal of Cellular and Molecular Immunology. 2015; 31: 1523–1527. (In Chinese)

[20] Du R, Zhao L, Xia L, Liu L, Sun W, Zhao A, et al. Association of URG11 and Twist with clinical pathological characteristics and prognosis in patients with IgA nephropathy. Nephrology Dialysis Transplantation. 2013; 28: 2268–2276.

[21] Mohapatra P, Madhulika S, Behera S, Singh P, Sa P, Prasad P, et al. Nimbolide-based nanomedicine inhibits breast cancer stem-like cells by epigenetic reprogramming of DNMTs-SFRP1-Wnt/b-catenin signaling axis. Molecular Therapy: Nucleic Acids. 2023; 34: 102031.

[22] Wu L, Ding W, Wang X, Li X, Yang J. Interference KRT17 reverses doxorubicin resistance in triple-negative breast cancer cells by Wnt/b-catenin signaling pathway. Genes Genomics. 2023; 45: 1329–1338.

[23] Zhang X, Dong N, Hu X. Wnt/b-catenin Signaling Inhibitors. Current Topics in Medicinal Chemistry. 2023; 23: 880–896.

[24] Raut D, Vora A, Bhatt LK. The Wnt/b-catenin pathway in breast cancer therapy: a pre-clinical perspective of its targeting for clinical translation. Expert Review of Anticancer Therapy. 2022; 22: 97–114.

[25] Jang G, Kim J, Cho S, Park K, Jung J, Lee H, et al. Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype. Scientific Reports. 2015; 5: 12465.

[26] Zhu L, Shi H, Li P, Zhang P. RNF43 suppressed triple-negative breast cancer progression by inhibiting Wnt/β-catenin pathway. Annals of Clinical and Laboratory Science. 2023; 53: 21–29.